WHO Drug Information Vol. 14, No. 4, 2000
(2000; 78 pages) Voir le document au format PDF
Table des matières
Ouvrir ce répertoire et afficher son contenuGeneral Policy Issues
Ouvrir ce répertoire et afficher son contenuVaccines and Biomedicines
Ouvrir ce répertoire et afficher son contenuGeneral Information
Fermer ce répertoireRegulatory and Safety Matters
Afficher le documentEtanercept: serious haematological reactions
Afficher le documentInfliximab: safety restrictions
Afficher le documentPhenylpropanolamine withdrawn from drug products
Afficher le documentLabelling revision for phenylpropanolamine
Afficher le documentPhenylpropanolamine advisory to consumers
Afficher le documentPhenylpropanolamine: strengthening of patient information
Afficher le documentLevacetylmethadol and cardiac disorders
Afficher le documentBovine-derived materials and vaccines: US recommendations
Afficher le documentProducts containing human albumin
Afficher le documentStavudine and didanosine: pregnancy advisory
Afficher le documentMethysergide and cardiac valvulopathy
Afficher le documentGreater control for cisapride
Afficher le documentNew combination drug for HIV
Afficher le documentTacrolimus for atopic dermatitis
Afficher le documentLetrozole approved for advanced breast cancer
Afficher le documentAlosetron withdrawn
Afficher le documentBasiliximab: hypersensitivity reactions
Afficher le documentBudipine: cardiac reactions
Afficher le documentCapecitabine: revised data sheet
Afficher le documentBenzathine penicillin: fatal mega-unit injections
Afficher le documentDisulfiram: hepatic reactions
Afficher le documentIsoniazid and rifampicin: severe skin reactions
Afficher le documentOmeprazole-induced interstitial nephritis
Afficher le documentOzagrel sodium: kidney function disorder
Afficher le documentDrug information to the public
Afficher le documentNorthern hemisphere influenza vaccine composition
Afficher le documentATC/DDD Classification (final)
Afficher le documentATC/DDD Classification (temporary)
Ouvrir ce répertoire et afficher son contenuHerbal Medicines
Ouvrir ce répertoire et afficher son contenuPublications and Sources of Information
 

Disulfiram: hepatic reactions

Sweden - Disulfiram is prescribed as an adjunct in the treatment of chronic alcoholism inhibiting the enzyme, aldehyde dehydrogenase. The combination of alcohol and disulfiram leads to an accumulation of acetaldehyde which induces classic symptoms such as flushing of the face, tachycardia, dyspnoea, nausea and vomiting.

Disulfiram may also cause severe liver injuries. In the Swedish Drug Reference List (FASS), liver damage is labelled as "a rare adverse reaction (<1/1000), usually with similar symptoms as for acute hepatitis and/or icterus as well as increased levels of SGOT and SGPT and bilirubin". This effect may be an allergic as well as toxic reaction.

In the Swedish adverse drug reactions register, SWEDIS, 149 case reports associated with disulfiram have been received since 1971. Of these reports there are 157 adverse reactions in total, of which 63 cite liver and biliary system disorders. Out of these 63 reports, seven have been classified as serious. The duration of treatment varied from five weeks to three months before onset of the reaction.

In three of these cases, the patients also took other drugs: sertraline, paroxetine and venlafaxine. These drugs may also be implicated in the reaction.

In three cases of severe liver damage with fatal outcome, disulfiram was suspected to have caused the reaction. If signs of liver damage should appear, it is recommended that disulfiram be discontinued and liver tests performed.

Reference: Information from the Medicines Product Agency, Volume 11, Number 5, 2000.

vers la section précédente vers la section suivante
 

Dernière mise à jour: le 3 mai 2013